Genmab — Maj 2020

[bibob]

ASCO: J&J 's anti - BCMA CAR-T improving with time sweeps Multiple Myeloma aside. https://www.fiercebiotech.com/biotech/asco-j-j-s-anti-bcma-car-t-improving-time-clears-multiple-myeloma?mkt_tok=eyJpIjoiWXpVME9USTBNRFF3T1RRNCIsInQiOiJoK21GN3phdVBuQkppUFwveVVidTMyVFcrbGVaaVZUZEcwTU9xemQwNFZ2dHNnK2lwSHl6VUNDNHFLOVZqRkdTeEgyVzE1b2YwTDNkeURiVE5SNllaVVI5TEN5WHR4WVA3NEp4bFNka2h5eHZtckNDcnU3VFlyMWlDVFwvdG1wTFhhM3lEVjBqMGR0OWFuWUczaFwvbmVTQlE9PSJ9&mrkid=41140432

[bibob]

Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

(www.fiercebiotech.com)

[E_L]

Daratumumab treatment in heavely pre-treated
immunoglobulin light chain amyloidosis https://cme-congresses.com/mailshotcme/COMy/2020/Abstracts/9.pdf

[Sukkeralf]

I still hope we will get that epcorita mab deal before ASCO - so my guess is either this weekend or next weekend. I would be nice to get that extra attention at ASCO. Maybe even more important in these Corona times so Genmab and Partner can keep this project moving as fast as possible

[Sukkeralf]

or maybe even in the ASCO weekend

[Sukkeralf]

Could we get phase III data in amyloidosis with sc dara as a late breaker at EHA instead of ASCO?

[E_L]

it is possible, submission deadline for late breaker for
EHA is about a month later i believe

[E_L]

I hope you are right on the epco deal for ASCO, but i am not sure Jan will feel much pressure ; we have been waiting soooo long; better get it right now...

[E_L]

Someone that knows him told me that, as nice as he is, he is actually a very very tough negotiator ...

[Solsen]

Nice to hear

[E_L]

4544 / 12 - Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models https://www.abstractsonline.com/pp8/#!/9045/presentation/7694

[E_L]

JNJ-61186372, an EGFR-cMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC) https://www.abstractsonline.com/pp8/#!/9045/presentation/5116

[E_L]

JNJ-61186372, an Fc enhanced EGFR/cMet bispecific antibody, mediates EGFR and cMet downmodulation and therapeutic efficacy preclinically through monocyte / macrophage mediated trogocytosis https://www.abstractsonline.com/pp8/#!/9045/presentation/7722

[E_L]

JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity https://www.abstractsonline.com/pp8/#!/9045/presentation/7733

[E_L]

haven't heard much about the CD33xCD3 duobody yet

[Sukkeralf]

i dont think so

[Sukkeralf]

Its funny they promote these newer DuoBodies - not much we hear about JNJ-63709178. 1 or 2 clinical holds so maybe not much to look forward to here

[E_L]

they did double the enrollment size not too long ago though on the -178 , that actually gave me little bit more hope

[E_L]

a few abstracts on BMS-986253
at ASCO (talking about something where i think there is not much to look forward to lol)

https://meetinglibrary.asco.org/results/986253?page=1

[E_L]

@Mohty_EBMT
presented an argument FOR the integration of anti-CD38 antibodies into induction therapies. https://twitter.com/MM_Hub/status/1261257388159635456